Durability data for newly-approved Vitrakvi on show

25 September 2019

As German pharma major Bayer (BAYN: DE) looks to expand its oncology offering, the latest new data will be presented at the annual meeting of the European Society for Medical Oncology (ESMO) this weekend.

The data on show will include a poster presentation on durability of response in adults and children with TRK fusion cancer treated with Vitrakvi (larotrectinib), a targeted medicine the firm picked up exclusive global rights to at the start of the year.

Last week, Vitrakvi became the first drug to receive a tumor-agnostic license in the European Union, following similar approvals in the USA, Brazil and Canada.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK